Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid

British Journal of Dermatology

Volumn 161, Issue 4, 2009, Pages 723-731

  Gurcan H M ^a   Razzaque Ahmed, A ^a  

^a NEW ENGLAND BAPTIST HOSPITAL   (United States)

Author keywords

Bullous pemphigoid; Methotrexate; Ocular cicatricial pemphigoid; Pemphigus foliaceus; Pemphigus vulgaris

Indexed keywords

CORTICOSTEROID DERIVATIVE; METHOTREXATE; PREDNISONE;

ADJUVANT THERAPY; ANEMIA; BACTERIAL INFECTION; BRONCHOPNEUMONIA; BULLOUS PEMPHIGOID; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; INTESTINE ULCER; MONOTHERAPY; MUCORMYCOSIS; NAUSEA; PANCYTOPENIA; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; REVIEW; SEPTICEMIA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; PEMPHIGOID, BULLOUS; PEMPHIGUS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 70349310516     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09246.x     Document Type: Review

References (61)

1. Genestier L, Paillot R, Quemeneur L et al. Mechanisms of action of methotrexate. Immunopharmacology 2000 47 : 247 257.
2. Bangert CA, Costner MI. Methotrexate in dermatology. Dermatol Ther 2007 20 : 216 228.
3. Scott JE, Ahmed AR. The blistering diseases. Office dermatology, Part II. Med Clin North Am 1998 82 : 1239 1283.
4. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol 1996 132 : 203 212.
5. Peck SM, Osserman KE, Samuels AJ et al. Studies in bullous diseases. Treatment of pemphigus vulgaris with immunosuppressives (steroids and methotrexate) and leucovorin calcium. Arch Dermatol 1971 103 : 141 147.
6. Lever WF, Goldberg HS. Treatment of pemphigus vulgaris with methotrexate. Arch Dermatol 1969 100 : 70 8.
7. Steinberg AD. An approach to the use of immunosuppressive drugs in nonmalignant diseases. J Allergy Clin Immunol 1973 52 : 242 250.
8. Burrows D, Shanks RG, Stevenson CJ. Methotrexate in dermatology. Br J Dermatol 1968 80 : 348 352.
9. Ryan JG. Pemphigus. A 20-year survey of experience with 70 cases. Arch Dermatol 1971 104 : 14 20.
10. Bystryn JC. Adjuvant therapy of pemphigus. Arch Dermatol 1984 120 : 941 951.
11. Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008 59 : 762 784.
12. Gottlieb A, Korman NJ, Gordon KB et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008 58 : 851 864.
13. Jablonska S, Chorzelski T, Blaszczyk M. Immunosuppressants in the treatment of pemphigus. Br J Dermatol 1970 83 : 315 323.
14. Piamphongsant T, Sivayathorn A. Pemphigus: combined treatment with methotrexate and prednisone. J Med Assoc Thai 1975 58 : 171 176.
15. Lever WF, Schaumburg-Lever G. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975. Arch Dermatol 1977 113 : 1236 1241.
16. Lever WF. Methotrexate and prednisone in pemphigus vulgaris. Therapeutic results obtained in 36 patients between 1961 and 1970. Arch Dermatol 1972 106 : 491 497.
17. Mashkilleyson N, Mashkilleyson AL. Mucous membrane manifestations of pemphigus vulgaris. A 25-year survey of 185 patients treated with corticosteroids or with combination of corticosteroids with methotrexate or heparin. Acta Derm Venereol 1988 68 : 413 421.
18. Smith TJ, Bystryn JC. Methotrexate as an adjuvant treatment for pemphigus vulgaris. Arch Dermatol 1999 135 : 1275 1276.
19. Rivitti EA, Camargo ME, Castro RM, Sampaio SA. Use of methotrexate to treat pemphigus foliaceus. Int J Dermatol 1973 12 : 119 122.
20. Downham TF 2nd., Chapel TA. Bullous pemphigoid: therapy in patients with and without diabetes mellitus. Arch Dermatol 1978 114 : 1639 1642.
21. Paul MA, Jorizzo JL, Fleischer AB Jr., White WL. Low-dose methotrexate treatment in elderly patients with bullous pemphigoid. J Am Acad Dermatol 1994 31 : 620 625.
22. Heilborn JD, Ståhle-Bäckdahl M, Albertioni F et al. Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. J Am Acad Dermatol 1999 40 : 741 749.
23. Dereure O, Bessis D, Guillot B, Guilhou JJ. Treatment of bullous pemphigoid by low-dose methotrexate associated with short-term potent topical steroids: an open prospective study of 18 cases. Arch Dermatol 2002 138 : 1255 1256.
24. Bara C, Maillard H, Briand N, Celerier P. Methotrexate for bullous pemphigoid: preliminary study. Arch Dermatol 2003 139 : 1506 1507.
25. McCluskey P, Chang JH, Singh R, Wakefield D. Methotrexate therapy for ocular cicatricial pemphigoid. Ophthalmology 2004 111 : 796 801.
26. Kjellman P, Eriksson H, Berg P. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol 2008 144 : 612 616.
27. Grattan CE. Evidence of an association between bullous pemphigoid and psoriasis. Br J Dermatol 1985 113 : 281 283.
28. Person JR, Rogers RS III. Bullous pemphigoid and psoriasis: does subclinical bullous pemphigoid exist? Br J Dermatol 1976 95 : 535 540.
29. Stüttgen G, Bockendahl H, Remy W, Lewicki D. [Psoriasis and bullous dermatoses]. Hautarzt 1978 29 : 134 140 (in German).
30. Koerber WA Jr., Price NM, Watson W. Coexistent psoriasis and bullous pemphigoid: a report of six cases. Arch Dermatol 1978 114 : 1643 1646.
31. Patton T, Korman N. Role of methotrexate in the treatment of bullous pemphigoid in the elderly. Drugs Aging 2008 25 : 623 629.
32. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005 57 : 163 172.
33. Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007 65 : 168 173.
34. Drosos A. Methotrexate intolerance in elderly patients with rheumatoid arthritis: what are the alternatives? Drugs Aging 2003 20 : 723 736.
35. Lovell DJ, Zaoutis TE, Sullivan K. Immunosuppressants, infection, and inflammation. Clin Immunol 2004 113 : 137 139.
36. Choy EH, Smith C, Doré CJ, Scott DL A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford) 2005 44 : 1414 1421.
37. Roenigk HH Jr., Auerbach R, Maibach H et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998 38 : 478 485.
38. Sato EI. Methotrexate therapy in systemic lupus erythematosus. Lupus 2001 10 : 162 164.
39. Gray O, McDonnell GV, Forbes RB. Methotrexate for multiple sclerosis. Cochrane Database Syst Rev 2004 2 : CD003208.
40. Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 2008 14 : 354 377.
41. Novak K, Swain MG. Role of methotrexate in the treatment of chronic cholestatic disorders. Clin Liver Dis 2008 12 : 81 96.
42. Chen KR, Carlson JA. Clinical approach to cutaneous vasculitis. Am J Clin Dermatol 2008 9 : 71 92.
43. Pipitone N, Salvarani C. Improving therapeutic options for patients with giant cell arteritis. Curr Opin Rheumatol 2008 20 : 17 22.
44. Henness S, Wigley FM. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review. Curr Opin Rheumatol 2007 19 : 611 618.
45. Joseph FG, Scolding NJ. Sarcoidosis of the nervous system. Pract Neurol 2007 7 : 234 244.
46. Coaccioli S, Giuliani M, Puxeddu A. The therapy of Sjögren's syndrome: a review. Clin Ter 2007 158 : 453 456.
47. Gong KZ, Song G, Spiers JP et al. Activation of immune and inflammatory systems in chronic heart failure: novel therapeutic approaches. Int J Clin Pract 2007 61 : 611 621.
48. Maksymowych WP. Update on the treatment of ankylosing spondylitis. Ther Clin Risk Manag 2007 3 : 1125 1133.
49. Inagaki J, Nagatoshi Y, Hatano M et al. Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children. Bone Marrow Transplant 2008 41 : 571 577.
50. Kuitunen T, Malmström J, Palva E, Pettersson T. Pancytopenia induced by low-dose methotrexate. A study of the cases reported to the Finnish Adverse Drug Reaction Register from 1991 to 1999. Scand J Rheumatol 2005 34 : 238 241.
51. Menter A, Gottlieb A, Feldman SR et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008 58 : 826 850.
52. National Patient Safety Agency. Improving compliance with oral methotrexate guidelines. NPSA Patient Safety Alert, June 2006. Available at: http://www.npsa.nhs.uk/EasySiteWeb/GatewayLink.aspx?alId=1494 (last accessed 7 May 2009).
53. British Association of Dermatologists. Methotrexate. Available at: http://www.bad.org.uk/site/1121/default.aspx (last accessed 7 May 2009).
54. Ortiz Z, Shea B, Suarez Almazor M et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000 2 : CD000951.
55. Collin B, Srinathan SK, Finch TM. Methotrexate: prescribing and monitoring practices among the consultant membership of the British Association of Dermatologists. Br J Dermatol 2008 158 : 793 800.
56. Maurice PD, Maddox AJ, Green CA et al. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen. Br J Dermatol 2005 152 : 451 458.
57. Chalmers RJ, Kirby B, Smith A et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 2005 152 : 444 450.
58. Zachariae H, Heickendorff L, Søgaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br J Dermatol 2001 144 : 100 103.
59. Yazici Y, Erkan D, Paget SA. Monitoring methotrexate hepatic toxicity in rheumatoid arthritis: is it time to update the guidelines? J Rheumatol 2002 29 : 1586 1589.
60. Yazici Y, Erkan D, Paget SA. Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events. Arthritis Rheum 2003 48 : 2769 2772.
61. Yazici Y, Erkan D, Harrison MJ et al. Methotrexate use in rheumatoid arthritis is associated with few clinically significant liver function test abnormalities. Clin Exp Rheumatol 2005 23 : 517 520.